Vetr upgraded shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) from a buy rating to a strong-buy rating in a research report sent to investors on Thursday morning. Vetr currently has $14.00 price objective on the biopharmaceutical company’s stock.
Several other analysts have also commented on the company. Northland Securities assumed coverage on Sucampo Pharmaceuticals in a research note on Wednesday, September 7th. They issued an outperform rating and a $15.00 price target on the stock. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, August 8th. Jefferies Group cut their price objective on Sucampo Pharmaceuticals from $16.00 to $14.00 and set a hold rating for the company in a research report on Thursday, August 4th. Mizuho downgraded Sucampo Pharmaceuticals from a buy rating to a neutral rating and set a $13.00 price objective for the company. in a research report on Thursday, August 4th. Finally, Maxim Group cut their price objective on Sucampo Pharmaceuticals from $26.00 to $17.00 and set a buy rating for the company in a research report on Monday, August 1st. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Sucampo Pharmaceuticals has an average rating of Buy and a consensus price target of $18.73.
Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 12.56 on Thursday. The company’s 50-day moving average price is $11.99 and its 200 day moving average price is $11.42. The company has a market cap of $537.69 million, a PE ratio of 44.07 and a beta of 1.57. Sucampo Pharmaceuticals has a 52 week low of $9.59 and a 52 week high of $21.27.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.01. The business had revenue of $52 million for the quarter, compared to analyst estimates of $48.33 million. Sucampo Pharmaceuticals had a return on equity of 42.18% and a net margin of 6.65%. Sucampo Pharmaceuticals’s quarterly revenue was up 49.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.21 EPS. On average, analysts anticipate that Sucampo Pharmaceuticals will post $1.03 EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. Macquarie Group Ltd. purchased a new stake in Sucampo Pharmaceuticals during the second quarter worth $228,000. Royal Bank of Canada increased its stake in Sucampo Pharmaceuticals by 22.3% in the second quarter. Royal Bank of Canada now owns 56,771 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 10,357 shares during the last quarter. Zacks Investment Management purchased a new stake in Sucampo Pharmaceuticals during the second quarter worth $110,000. Marshall Wace LLP purchased a new stake in Sucampo Pharmaceuticals during the second quarter worth $356,000. Finally, Menta Capital LLC increased its stake in Sucampo Pharmaceuticals by 191.5% in the second quarter. Menta Capital LLC now owns 178,582 shares of the biopharmaceutical company’s stock worth $1,959,000 after buying an additional 117,310 shares during the last quarter. Institutional investors own 40.64% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.